Goodwin advised Nuvig Therapeutics on the deal. Nuvig Therapeutics announced its $47 million Series A financing and the launch of the company to develop novel therapeutics that […]
Nuvig Therapeutics’ $47 Million Series A Financing
OPKO Health’s Acquisition of ModeX Therapeutics
Goodwin advised ModeX Therapeutics, Inc. on the deal. ModeX Therapeutics, Inc. announced its sale to OPKO Health, Inc. (NASDAQ: OPK) for $300 million in OPKO common stock. […]
Flagship Pioneering’s Collaboration Agreement with Novo Nordisk A/S
Goodwin Procter advised Flagship Pioneering on the deal. Flagship Pioneering announced its collaboration agreement with Novo Nordisk A/S to create a portfolio of novel research programs […]
MOMA Therapeutics’ $150 Million Series B Financing
Goodwin Procter advised MOMA Therapeutics on the deal. MOMA Therapeutics announced its completion of a $150 million Series B Financing. MOMA Therapeutics is a biopharmaceutical company […]
Shopify’s Acquisition of Deliverr
Goodwin Procter advised Deliverr, Inc. on the deal. Deliverr, Inc. announced its agreement to be acquired by Shopify Inc. (NYSE, TSX: SHOP). Under the terms of the […]
TA Associates’ Investment in Veracode
Goodwin Procter advised TA Associates on the deal. TA Associates announced its strategic growth investment in Veracode, taking a majority equity position in the business. Veracode is […]
Germitec’s €11 Million Financing Round
Goodwin advised Germitec on the deal. Germitec, a global healthcare leader in high-Level UV-C disinfection systems, announced the financing round of €11 million. Reference investors in the […]
Shutterstock’s $210 Million Acquisition of Pond5
Goodwin Procter advised Pond5 on the deal, while Cahill advised Shutterstock in the acquisition and in a $100 million revolving credit facility. Pond5 announced its acquisition by […]
York Capital Management’s Acquisition of Lincsafe, Merlin, Cashtester and Secusystems
Goodwin Procter advised York Capital Management on the deal. York Capital Management announced an acquisition through its portfolio company, Cennox, of a group of Dutch-based companies including […]
PepGen’s $108 Million Initial Public Offering
Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with […]
Alan’s €183 Million Fundraising
Goodwin advised Ontario Teachers’ Pension Plan (OTPP) while Orrick represented Alan. Ontario Teachers’ Pension Plan (OTPP) led the $193 million Series E financing round of the French […]
GFBiochemicals’ €15 Million Series A Fundraising
Goodwin Procter advised GFBiochemicals on the deal. GFBiochemicals, a leading sustainable chemical company and its founder, Mathieu Flamini, announced its €15 million Series A fundraising. Led by […]